Performance: The future of cell therapy is to be xenogeneic-free and therefore human platelet lysate offers xenogeneic free/serum substitutes for replacing FBS and improving cell culture performance.
Cost: FBS is commonly used at concentration between 10-20% in cell culture. However due to the high performance effects of human platelet lysate, it is typically used at lower concentrations; 2.5%, 5% or 10%, which shows the same effects compared to FBS. So when comparing costs, you should compare hPL to nearly 4x your current FBS cost.
Batch-to-batch variation: Batch-to-batch variability of hPL is significantly lower than FBS since is derived from standardized human blood products. As hPL is obtained from multiple donors units that are subsequently pooled in large batch sizes, it enables the manufactured of a consistent product with minimal lot-to-lot variation.